Usage Dosage:

1. This product is an insulin analog with a long-acting effect and should be injected once a day at dusk.The OptiSet injection device dose adjustment starts at 2 IU, with a maximum single injection dose of 40 IU.The dosage of glucagon insulin should be varied from person to person.

2. Patients with type 2 diabetes can also use glucagon together with oral hypoglycemic agents. When changing from other insulin treatments to insulin glargine from other intermediate-acting or long-acting insulin treatment plans to insulin glargine, it may be necessary to change the dosage of the basal insulin and adjust the other medications that are also being used in the treatment of diabetes mellitus (addition of the amount and duration of injection of general insulin or rapid-acting insulin analogs, or the dosage of oral hypoglycemic medications).

3. In order to reduce the risk of hypoglycemia at night and in the early morning, when the patients who originally choose to inject NPH insulin twice a day are changed to the treatment plan of injecting insulin with glucagon once a day, the dosage of basal insulin should be reduced by 20-30% in the first week of the change of treatment. In the first week to reduce the amount of basal insulin, some patients may need to compensate for the use of insulin when eating, and then the treatment plan should be different from person to person. Patients on high doses of insulin due to anti-human insulin antibodies, as with other insulin analogs, may have an increased insulin response after switching to insulin glargine. Metabolic changes should be monitored closely during the first few weeks of switching to and starting glucagon insulin. As metabolic control improves and insulin sensitivity increases, further adjustments to the dosage schedule may be necessary. Dosage adjustments may also be necessary if the patient's weight or lifestyle changes, or if conditions predisposing to hypoglycemia or hyperglycemia are present.

Usage:

Glycine insulin should be administered by subcutaneous injection. Do not administer glucagon intravenously. The long-lasting effects of glucagon are related to its injection within the subcutaneous arrangement. Severe hypoglycemia can occur if the usual subcutaneous dose of the drug is injected intravenously. No clinical differences in serum insulin or glucose levels were seen after subcutaneous injections into the abdomen, deltoid muscle, or thigh. Within a given injection zone, the site of each injection must be rotated.

Due to limited experience, the safety and efficacy of glycemic insulin in the following patient populations have yet to be evaluated: juveniles, patients with hepatic jeopardy or moderate to severe renal jeopardy.

Precautions:

For the treatment of diabetic ketoacidosis, glycemic insulin is not an option; intravenous conventional insulin is recommended.

C Patients with renal impairment may require less insulin due to slowed insulin metabolism. In the elderly and patients with progressive renal failure, the need for insulin may gradually decrease.

Patients with severe hepatic damage may have a decreased need for insulin due to decreased gluconeogenesis and decreased insulin metabolism.

In patients with poor glycemic control or a predisposition to episodes of hyperglycemia or hypoglycemia, a thorough review of whether the patient is being treated according to the intended regimen, the site of injection, proper injection technique, and all other relevant factors should be reviewed before considering a dose adjustment.

Hypoglycemic reactions: the time to onset of hypoglycemia depends on the action characteristics of the insulin used and therefore may change with changes in the treatment regimen.

The information is from the Internet and is for reference only.